CCM Biosciences

Non-confidential Overview

August 2023

CCM BioSciences at a Glance

•CCM Biosciences is funded by Chakrabarti Capital Management (CCM), an evergreen fund

with a focus on start-up stage biotech companies

•CCM’s corporate limited partner is PMC Group, Inc., a global chemical and pharmaceutical

conglomerate with 25+ year track record in chemicals/pharmaceuticals investment

management, the Chakrabarti family’s holdings have ~$1.5B equity value and are 100%

owned by the family.

•CCM Biosciences, the company building division of the holdings, has assembled a portfolio

of disruptive pharmaceutical assets many of which are first-in-class or best-in-class drug

programs, housed under 6 divisions

•The assets originate from in-house development and co-development with leading

academic institutions

•The pipeline spans precision oncology, autoimmune disorders and chronic, age-related

diseases and modalities and includes small molecules, biologics and nano-medicines

•CCM Biosciences has access to expert pharmaceutical development capabilities from the

PMC Group’s CRDMO division providing an agile and cost-effective development model.

CCM’s Corporate LP is a Global Chemical & CRO Conglomerate

Renewable Oleochemicals and Derivatives

Organometallic Specialties

Defoamers and Process Additives

Functional Polymer Additives

Formulated Chemical Specialties

Fine Chemicals

Pharmaceutical Intermediates and Active Ingredients

Custom Pharmaceutical Manufacturing

COPPERHEAD PHARMA Finished Dosage Forms

North America

Mount Laurel, NJ (HQ)

Memphis, TN

Carrollton, KY

Mobile, AL

Stockertown, PA

Lansdale, PA

Asia

Beijing, China

Kyungju, South Korea

Rishra, India

Hyderabad, India

Europe

Carvin, France

Vert Le Petit, France

Pithiviers, France

Gennevilliers, France

Vlissingen, Netherlands

‘In-House’ development capabilities providing cost effective &

agile development and feeding the pipeline

Center for Protein Engineering and Drug Discovery CRO

Approx 20 staff

PMC Isochem Pithiviers CRO

Approx 80 staff

DRUG DISCOVERY PRE-CLINICAL PHASE CLINICAL PHASE DRUG LAUNCH

HITS IDENTIFICATION BY HTS

HITS OPTIMIZATION AND

CONFIRMATION

HITS SYNTHESIS

FORMULATION STUDIES

LEAD SYNTHESIS

RAW MATERIAL AVAILIBILITY

PROCESS CHEMISTRY ASSESSMENT

SCALE-UP FEASIBILITY

REGULATORY ASSESSMENT

CHEMICAL PROCESS DEVELOPMENT

ANALYTICAL DEVELOPMENT AND

METHOD VALIDATION

PROCESS SCALE-UP

GMP MANUFACTURING

LARGE SCALE MANUFACTURING

DRUG DISCOVERY PRE-CLINICAL PHASE CLINICAL PHASE DRUG LAUNCH

Drug Discovery

- Small molecules

- Peptides /

Proteins

- Polymers

Drug Delivery

- Non polymer Excipients

- Polymer - Excipients

- Polymer conjugates

CDMO

- Small molecules : API &

Intermediates

- Excipients

- Peptides

- Polymers

- Polymer conjugates

NCE/NBE

•Phage display

•DEL

•Hit and Hit to lead

•Machine learning and

computational biophysics

Proteins/enzymes

•Protein engineering

•Enzymes selection &

optimization

•Machine learning and

computational biophysics

PAAs

•ROP of NCAs

•PAAs based polymers

Chemistry

•Dev. scale-up & CMC

•Manufacturing

Biocatalysis

•Dev. Scale-up & CMC

•Manufacturing

Platform Tech (Methods IP) Licensed

from

Drug discovery and development platforms

CCM’s Biotechnology Portfolio (CCM Biosciences)CCM Biosciences Portfolio Overview

CCM RAS Sciences

CDK6

Autophagy

CCM Immune Sciences

Autoimmune Disorders

cGAS TLR9

SIRT

CCM Nanothera Sciences

Nanoformulation, Antibody

Targeting & Gene Therapy

Injectables

Topo-

isomerase/

PAA

EGFRvIII /

ADCM

KRAS

Gene

therapy

CCM Biosciences, Inc.

CCM Protein Upregulation

Novel Drug Mechanisms

Alliance with a major Italian Foundation

ALK/EGFR Nonsense

Mutations

CCM PROTAC Sciences

Receptor Kinases

Oral Therapeutics

Color coding: modalities employed (blue = small molecule, green = biologic/nanomedicine; purple = genomics): text = API; border = delivery vehicle

Platform IP required to discover/ develop assets are licensed from PMC Advanced Technology to CCM Biosciences.

CCM 5Prime Sciences

Engineered enzymes enabling liquid biopsy CDx,

manufacturing of gene therapy APIs, and

enzymatic DNA synthesis

Alliance with Quest, Celera/Abbott, New

England Biolabs, Toyobo/Sekisui Diagnostics

DNA

Biologics

Novel IVD

tests

Synthetic

Biology